{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:09:50Z","timestamp":1747170590682,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.schres.2019.07.033","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T12:09:17Z","timestamp":1564661357000},"page":"100-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Examination of heterogeneity in treatment response to antipsychotic medications"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-2075","authenticated-orcid":false,"given":"Natalie","family":"Bareis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Scott","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.schres.2019.07.033_bb0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1176\/appi.ps.002412012","article-title":"Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study","volume":"64","author":"Arnold","year":"2013","journal-title":"Psychiatr. Serv."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.07.033_bb0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.schres.2007.12.470","article-title":"The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder","volume":"100","author":"Byerly","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2019.07.033_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"issue":"1","key":"10.1016\/j.schres.2019.07.033_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/schbul\/16.1.57","article-title":"Diagnosis of alcohol use disorders in schizophrenia","volume":"16","author":"Drake","year":"1990","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.schres.2019.07.033_bb0025","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2019.07.033_bb0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0010-440X(91)90085-Q","article-title":"SCID-PANSS: two-tier diagnostic system for psychotic disorders","volume":"32","author":"Kay","year":"1991","journal-title":"Compr. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2019.07.033_bb0035","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2019.07.033_bb0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2019.07.033_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.schres.2019.07.033_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"issue":"19","key":"10.1016\/j.schres.2019.07.033_bb0055","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.schres.2019.07.033_bb0060","doi-asserted-by":"crossref","first-page":"c83","DOI":"10.1159\/000324758","article-title":"Survival analysis I: the Kaplan-Meier method","volume":"119","author":"Stel","year":"2011","journal-title":"Nephron Clin. Pract."},{"issue":"1","key":"10.1016\/j.schres.2019.07.033_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T15:55:07Z","timestamp":1721577307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419303135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":13,"alternative-id":["S0920996419303135"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.07.033","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examination of heterogeneity in treatment response to antipsychotic medications","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}